Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1/2 2

Status

Recruiting 2Withdrawn 1Not yet recruiting 1

Sponsor Class

OTHER 2INDUSTRY 2

Study Type

Interventional 4Observational 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Breast Neoplasms 2419Neoplasms 1838Carcinoma, Non-Small-Cell Lung 1591Prostatic Neoplasms 1296Colorectal Neoplasms 1117Lung Neoplasms 981Neoplasm Metastasis 828Multiple Myeloma 793Leukemia, Myeloid, Acute 773Ovarian Neoplasms 673Pancreatic Neoplasms 667Melanoma 660Squamous Cell Carcinoma of Head and Neck 589Recurrence 563Carcinoma, Hepatocellular 562Brain Neoplasms 515Glioblastoma 505Stomach Neoplasms 501Head and Neck Neoplasms 492Triple Negative Breast Neoplasms 471Lymphoma 460Uterine Cervical Neoplasms 444Carcinoma, Renal Cell 426Precursor Cell Lymphoblastic Leukemia-Lymphoma 420Lymphoma, Non-Hodgkin 387Endometrial Neoplasms 377Sarcoma 365Lymphoma, Follicular 357Urinary Bladder Neoplasms 356Lymphoma, Large B-Cell, Diffuse 355

Interventions

Leucovorin 2Irinotecan 2Fluorouracil 2spartalizumab 1pembrolizumab 1Radiosurgery 1Oxaliplatin 1Oncolytic Virotherapy 1IFL protocol 1Folfox protocol 1Drug Therapy 1Cetuximab 1Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Interventional × CRC × 1 year × Clear all
NCT07283367 2026-05-01

A Phase Ib/II Trial of HS-20110 Combination Therapies in Advanced Colorectal Cancer Patients.

Hansoh BioMedical R&D Company

Phase 1/2 Recruiting
502 enrolled

CRC

NCT07381309 2026-04-28

VVSHIP

Sixth Affiliated Hospital, Sun Yat-sen University

Phase 2 Not yet recruiting
114 enrolled
Gastrointestinal

CRC

NCT07511972 2026-04-06

Study of NGM707 in Combination With Pembrolizumab in Advanced or Metastatic Solid Tumor Malignancies

NGM Biopharmaceuticals, Inc

Phase 2 Withdrawn

CRC

NCT07204574 2025-10-02

The Phase 1b/IIa, Open-label, Dose Escalation and Dose Expansion to Evaluate Safety, Tolerability, and Preliminary Efficacy of the Combination of HCB101, Cetuximab/Bevacizumab, and FOLFOX/FOLFIRI in Advanced or Metastatic Colorectal Cancer

Chang Gung Memorial Hospital

Phase 1/2 Recruiting
40 enrolled

CRC

Data powered by HemOnc (CC BY 4.0) Colophon âš¡